Express Scripts sees no let-up in drug pricing chatter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Mizuho Securities Remains Sidelined on Express Scripts (ESRX) Following 2017 Guidance
December 14, 2016 1:16 PM ESTMizuho Securities reiterated a Neutral rating and $76.00 price target on Express Scripts (NASDAQ: ESRX) following the company's initial 2017 guidance. 2017 adjusted EPS guidance is $6.82-$7.02, relatively in-line with consensus of $6.93 at the midpoint ($6.92), implies a +7-10% adjusted EPS growth y/y.
Analyst Ann Hynes commented,... More
